^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
AmoyDx® Pan Lung Cancer PCR Panel

Type:
Other Approval
Related tests:

Details

Evidence
Twitter
AmoyDx Pan Lung Cancer Panel is qualitative detection of 167 hotspot alterations in EGFR, ALK, ROS1, KRAS, BRAF, HER2, RET, MET, NTRK1, NTRK2 and NTRK3 genes in NSCLC at a time from a single tissue specimen. The assay contains DNA-based mutation detection and mRNA-based fusion detection. The RNA gene fusion detection includes two processes: 1) Reverse Transcription, 2) PCR Amplification. The DNA gene mutation detection system uses ADx-ARMS technology.
Cancer:
Non Small Cell Lung Cancer
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase)
See More ...
Drug:
Lumakras (sotorasib), Rozlytrek (entrectinib), Tepmetko (tepotinib), gumarontinib (SCC244)
Method:
RT-PCR